Stockscreener 앱 받기
306.38
2.88%
-9.10
시간 외 거래:
306.38
전일 마감가:
$315.48
열려 있는:
$316
하루 거래량:
302.75K
Relative Volume:
0.85
시가총액:
$7.36B
수익:
-
순이익/손실:
$-518.67M
주가수익비율:
-12.20
EPS:
-25.12
순현금흐름:
$-438.32M
1주 성능:
-7.52%
1개월 성능:
-2.55%
6개월 성능:
-9.25%
1년 성능:
+33.30%
1일 변동 폭
$304.50
$318.27
1주일 범위
$304.50
$349.00
52주 변동 폭
$200.08
$377.46
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
명칭
Madrigal Pharmaceuticals Inc
전화
404-380-9263
주소
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
MDGL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
306.38 | 7.36B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-28 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | 재확인 | H.C. Wainwright | Buy |
| 2024-06-28 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-04-22 | 개시 | BofA Securities | Underperform |
| 2024-03-15 | 업그레이드 | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-02-26 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | 재확인 | Oppenheimer | Outperform |
| 2022-12-19 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-19 | 재확인 | Piper Sandler | Overweight |
| 2022-12-19 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-11-24 | 재개 | Evercore ISI | Outperform |
| 2020-11-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-05 | 개시 | BMO Capital Markets | Market Perform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-01-30 | 개시 | Canaccord Genuity | Buy |
| 2020-01-09 | 업그레이드 | UBS | Neutral → Buy |
| 2019-11-07 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-25 | 개시 | Stifel | Hold |
| 2019-06-10 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-12-12 | 개시 | B. Riley FBR | Neutral |
| 2018-11-19 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-09-04 | 개시 | Citigroup | Buy |
| 2018-08-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2018-06-28 | 개시 | Raymond James | Mkt Perform |
모두보기
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT I - GuruFocus
(MDGL) Trading Signals - news.stocktradersdaily.com
Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raise - GuruFocus
Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost fr - GuruFocus
Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost from B. Riley Securities | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals (MDGL) Target Price Raised by Canaccord Genuity | MDGL Stock News - GuruFocus
UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | - GuruFocus
Madrigal Pharmaceuticals to Present Breakthrough Resmetirom Data at EASL Congress 2025 - MSN
UBS Adjusts Madrigal Pharmaceuticals Price Target to $458 From $441, Maintains Buy Rating - marketscreener.com
Madrigal Pharmaceuticals (MDGL) Receives Increased Price Target from Analyst | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals Inc (MDGL) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Madrigal Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Madrigal: Q1 Earnings Snapshot - Huron Daily Tribune
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up - Yahoo Finance
Madrigal Pharmaceuticals Q1 Loss Narrows - marketscreener.com
Earnings call transcript: Madrigal Pharmaceuticals beats Q1 2025 EPS forecasts - Investing.com
Madrigal Pharmaceuticals Inc Q1 2025 Earnings: Revenue Surpasses - GuruFocus
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates - The Manila Times
Madrigal Pharmaceuticals (MDGL) Reports Strong Q1 Revenue Exceed - GuruFocus
Madrigal’s MASH drug sales again top Wall Street projections - Yahoo Finance
Madrigal stock holds neutral as 1Q revenue beats estimates By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals (MDGL) to Present Key Findings at EASL - GuruFocus
Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress - The Manila Times
Madrigal to Present Late-Breaking Resmetirom Data in - GlobeNewswire
Insiders At Madrigal Pharmaceuticals Sold US$4.4m In Stock, Alluding To Potential Weakness - simplywall.st
Citizens JMP reiterates Madrigal stock with $443 target By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals to Announce Q1 2025 Results with Live Webcast - MSN
Leadership Changes at Madrigal Pharmaceuticals Mark New Phase of Growth - MSN
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals to Release Q1 2025 Financial Results on May 1, 2025 - Nasdaq
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 - GlobeNewswire
Madrigal Pharmaceuticals announces executive transition By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals announces executive transition - Investing.com Australia
Madrigal Pharmaceuticals Announces Leadership Transition - TipRanks
(MDGL) Technical Data - news.stocktradersdaily.com
Madrigal founder Rebecca Taub to step back; firm hires successor from Novartis - The Business Journals
Madrigal Pharmaceuticals Appoint Rebecca Taub, M.D. as Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed CMO - citybiz
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer - The Manila Times
Madrigal Pharmaceuticals Announces Company Founder Rebecca - GlobeNewswire
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, - GuruFocus
Madrigal Pharmaceuticals Announces Changes to Board of Directors - MSN
Madrigal Pharmaceuticals to Announce Q4 and Full-Year 2024 Results with Live Webcast - MSN
Trend Tracker for (MDGL) - news.stocktradersdaily.com
Cytokinetics, Madrigal, and BridgeBio Emerge as Potential Pharma Takeover Targets - GuruFocus
Is Madrigal Pharmaceuticals (MDGL) The Most Expensive Stock Insiders Are Dumping In March? - Yahoo
Madrigal (MDGL) Up 0.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
20 Most Expensive Stocks Insiders Are Dumping In March - Insider Monkey
Analysts Expect Breakeven For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Before Long - simplywall.st
(MDGL) On The My Stocks Page - Stock Traders Daily
Madrigal Pharmaceuticals Inc (MDGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):